| Project/Area Number |
25870440
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Endocrinology
Laboratory medicine
|
|---|
| Research Institution | Tottori University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
TANIGUCHI Shin-ichi
MATSUZAWA Kazuhiko
OHKURA Hiroko
ISHIGURO Kiyosuke
NOGUCHI Hitoshi
KIKUCHI Tadashi
HINO Tomoya
KOGA Atsuro
|
|---|
| Project Period (FY) |
2013-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 甲状腺癌 / SEREX / ELISA / WD repeat domain 1 / Fibronectin 1 / autoantibody / 抗WDR1抗体価 / 甲状腺乳頭癌 / エピトープマッピング / 血清診断 / スクリーニング / 甲状腺未分化癌 |
|---|
| Outline of Final Research Achievements |
We promoted a basic research to investigate novel and inexpensive serological biomarkers for differentiating thyroid carcinoma, not dependent on common diagnostic method using ultrasound (US) and fine needle aspiration cytology (FNAC). To differentiate high-risk patients with papillary thyroid carcinoma (PTC), which consisted of more than 90% of thyroid carcinoma, we focused on WD repeat domain 1 (WDR1) and Fibronectin 1 (FN1) isolated from undifferentiated thyroid carcinoma (UTC). We conducted artificially-generated peptides consisted of 12 amino acids originated from WDR1 and FN1, and finally isolated specific peptides interacted to autoantibodies in the sera of PTC with poor prognosis.
We are now developing a new diagnostic method for detecting autoantibodies associated with prognosis of PTC.
|
| Academic Significance and Societal Importance of the Research Achievements |
甲状腺癌の多くは自覚症状に乏しく、進行が緩徐な甲状腺乳頭癌である。従来の検査方法では、早期に治療必要性の高い患者さんのみを簡便に発見し、治療することが困難であった。本研究の成果は、簡便な血液検査により治療が必要な甲状腺癌の患者さんを発見することにつながるものである。本研究成果が臨床応用されることにより、超音波検査や細胞診検査をはじめとする従来の検査を要さず病状の予測が可能となり、検査を受ける患者さんおよび検査を実施する医療従事者の負担軽減が期待される。
|
